ICMJE DISCLOSURE FORM

Date:	12/12/2023
Your Name:	Astrid van Tubergen
Manuscript Title:	De groeiende groep biologicals binnen de reumatologie – hoe door de bomen het bos te blijven zien
Manuscript Number (if known):	D8051

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.		
	ı	Time frame: past 36 months			
2	Grants or contracts from	□ None			
	any entity (if not	Pfizer	Unrestricted grant to institution		
	indicated in item	UCB	Unrestricted grant to institution		
	#1 above).	Novartis	Unrestricted grant to institution		
3	Royalties or licenses	None Non			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	Novartis Galapagos Johnson and Johnson UCB	Advisory board, payment to institution
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None Pfizer Novartis	Speakers bureaus, payment to institution Speakers bureaus, payment to institution
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None		
13	Other financial or non-financial interests	None		
Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.				